DISCUSSION GUIDE

ONCE-DAILY rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%

Questions for your doctor

Use the questions below to help jumpstart the conversation with your doctor and learn if Rocklatan® is the right treatment for your open-angle glaucoma or ocular hypertension.

Is Rocklatan® right for me?

What makes Rocklatan® different from other medications?

Can I take Rocklatan® with other drops or medications?

Are there any possible side effects I should know about before taking Rocklatan®?

How do I use Rocklatan®?

How will I know if Rocklatan® is working?

Is there any way I can save on my Rocklatan® prescription?

How do I store Rocklatan®?

Can I take Rocklatan® if I wear contact lenses?

What if I forget to take Rocklatan® or decide to stop taking it?

To learn more about Rocklatan®, including additional safety and co-pay information, please visit Rocklatan.com.

IMPORTANT SAFETY INFORMATION

Contraindications
None.

Warnings and Precautions
Rocklatan® contains latanoprost, which may cause darkening of the eye color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes. Color changes may increase as long as Rocklatan® is administered, and eye color changes are likely to be permanent. Eyelash changes are usually reversible upon discontinuation of treatment.

Rocklatan® should be used with caution and may cause inflammation inside the eye or make existing inflammation worse.

Appointment notes

Left eye

Current pressure level: _____ mmHg

Target pressure level: _____ mmHg

Right eye

Current pressure level: _____ mmHg

Target pressure level: _____ mmHg

My next appointment is: _____

Additional notes

_____

_____

_____

IMPORTANT SAFETY INFORMATION (continued)

Warnings and Precautions (continued)
Rocklatan® may cause macular edema (swelling of the macula) and should be used with caution in patients without a natural lens, in patients with a torn posterior lens capsule who have an artificial lens implant, or in patients with known risk factors for macular edema.

Rocklatan® should be used with caution in patients with a history of herpetic keratitis and not used in patients with active herpes simplex keratitis.

Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.

Contact lenses should be removed prior to using Rocklatan®. Contact lenses can be reinserted 15 minutes following administration of Rocklatan®.

If you have eye surgery, eye trauma or infection, or develop any eye reactions, immediately consult with your physician about continuing treatment with Rocklatan®.

Adverse reactions
The most common side effect for Rocklatan® in controlled clinical studies were red eyes (59%). Five percent of patients discontinued therapy due to red eyes. Other common side effects were pain upon instillation of eye drop (20%), small deposits on the outer surface of the eye (corneal verticillata) (15%), and broken blood vessels (11%). Eye itching, visual acuity reduced, excessive tearing, eye discomfort upon administration of eye drop, and blurred vision were reported in 5-8% of patients.

Be sure to contact your doctor if you have any questions.

Please visit Rocklatan.com for full prescribing information for Rocklatan®.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Indications and Usage
Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a prescription medication for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

Dosage and Administration
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used together with other eye drops to lower high eye pressure/IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

aerie Pharmaceuticals, Inc.

www.aeriepharma.com